PRA Health Sciences (PRAH) Set to Announce Quarterly Earnings on Monday

PRA Health Sciences (NASDAQ:PRAH) will issue its quarterly earnings data after the market closes on Monday, April 23rd. Analysts expect the company to announce earnings of $0.83 per share for the quarter. PRA Health Sciences has set its FY18 guidance at $4.00-4.15 EPS.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, February 21st. The medical research company reported $1.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.02. The company had revenue of $568.80 million during the quarter, compared to the consensus estimate of $543.78 million. PRA Health Sciences had a return on equity of 22.77% and a net margin of 3.85%. The firm’s revenue for the quarter was up 37.5% compared to the same quarter last year. During the same period last year, the business posted $0.71 EPS. On average, analysts expect PRA Health Sciences to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

How to Become a New Pot Stock Millionaire

Shares of PRAH opened at $87.00 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.90 and a quick ratio of 0.90. The stock has a market capitalization of $5,512.17, a PE ratio of 27.19, a PEG ratio of 1.38 and a beta of 0.49. PRA Health Sciences has a one year low of $61.93 and a one year high of $95.90.

Several brokerages have recently commented on PRAH. BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Mizuho downgraded PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 target price for the company. in a research note on Wednesday, January 24th. Zacks Investment Research downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Finally, KeyCorp restated a “buy” rating and issued a $100.00 target price on shares of PRA Health Sciences in a research note on Wednesday, January 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. PRA Health Sciences has a consensus rating of “Buy” and an average price target of $95.67.

In other PRA Health Sciences news, VP Linda Baddour sold 67,000 shares of PRA Health Sciences stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total transaction of $6,048,090.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.10% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “PRA Health Sciences (PRAH) Set to Announce Quarterly Earnings on Monday” was published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://weekherald.com/2018/04/16/pra-health-sciences-prah-set-to-announce-quarterly-earnings-on-monday.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Earnings History for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply